Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.
  • Posted by Richa Munjal
  • May 27, 2019
  • Articles

Hyperlipidemia: Are the PCSK9 inhibitors bouncing back?

Hyperlipidemia: Are the PCSK9 inhibitors bouncing back?

This article, published by Pharma Times May 2019, considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs.

The promise of a new era of cholesterol management, heralded by the launch of highly effective PCSK9 inhibitors, has been complicated by significant barriers to uptake of the next-generation products in multiple markets. These obstacles partly reflect initial premium pricing of the two available PCSK9 inhibitors, Praluent (alirocumab) and Repatha (evolocumab). Price differentials have been all the more marked given the established reliability of low-cost, genericised statins as a tool for lowering cholesterol. In that light, many physicians, thought leaders and payers opted to wait for persuasive outcomes data that would substantiate the ability of the PCSK9 inhibitors to offset higher costs with long-term gains in preventing mortality, hospitalisation or other serious cardiovascular events.

read more »

  • Posted by Mariel Metcalfe
  • May 24, 2019
  • News

Research Partnership publishes new patient Living with Non-alcoholic Steatohepatitis (NASH) EU report

Research Partnership publishes new patient Living with Non-alcoholic Steatohepatitis (NASH) EU report

Living with Non-alcoholic Steatohepatitis (NASH) EU is a study conducted amongst 275 adults with NASH / NAFLD in France, Germany, Italy, Spain and UK. The report consists of 30-minute quantitative online and qualitative telephone interviews with patients. The report, which is now available for purchase, enables pharmaceutical companies developing products in this disease area to gain a deeper understanding of how patients come to be diagnosed with NASH, how it impacts their day-to-day lives and what their attitudes and perceptions are towards the management of their condition.

read more »

  • Posted by Mariel Metcalfe
  • May 24, 2019
  • News

Research Partnership publishes new patient Living with Atopic Dermatitis (EU) 2019 report

Research Partnership publishes new patient Living with Atopic Dermatitis (EU) 2019 report

Living with Atopic Dermatitis (AD) is a new quantitative study conducted amongst 403 adults living with the disease and 141 caregivers of children with AD in France, Germany, Italy, Spain and UK. 

read more »

  • Posted by Liza Pliss
  • May 24, 2019
  • Webinars

Usability and UX: You’ve been asked to test… what next?

Usability and UX: You’ve been asked to test… what next?

Join us Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST

The healthcare industry is increasingly using digital channels to deliver information and services to its customers. However, for these to be effective and increase brand satisfaction, it’s critical that patients, HCPs, and any other stakeholders have a positive user experience.
 

read more »

  • Posted by Liza Pliss, Sabera Hyderally and Emily Hoffman
  • May 23, 2019
  • Events

Intellus Worldwide Summit round up 2019

Intellus Worldwide Summit round up 2019

This May, Liza Pliss, Director and Head of our New York Office, Sabera Hyderally, Director, Head of MedTech Division North America and Emily Hoffman, Associate Director exhibited at and attended the Intellus Worldwide Summit in Philadelphia.

read more »